| Name | Ceruletide |
| Description | Ceruletide is a decapeptide that serves as a safe and effective cholecystokinin receptor agonist, exerting a direct spasmogenic effect on the gallbladder muscle and bile ducts, and is commonly used to establish pancreatitis models. |
| In vitro | Ceruletide is biologically and chemically identical to the human gastrointestinal hormones cholecystokinin-pancreatin (CCK) and gastrin II；Ceruletide stimulates gallbladder contraction while delaying gastric emptying and inhibiting motility of the proximal duodenum [1]. Ceruletide activates NF-κB/Rel in vitro at high doses (but not physiological doses), which may induce a self-defense gene program before cell damage occurs and may protect pancreatic acinar cells from further damage after secretagogue overstimulation [2]. |
| In vivo | Ceruletide (5-15 ng/kg intravenously) has a significant spasmodic effect on the pylorus in rats[1]; Ceruletide (0.4-0.5 mcg/kg intravenously; 3-4 mcg/kg subcutaneously) causes vomiting and defecation in conscious dogs [3]. |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 255 mg/mL (188.55 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 5 mg/mL (3.7 mM), Sonication is recommended.
H2O : 5 mg/mL (3.7 mM), Sonication is recommended.
|
| Keywords | Inhibitor | inhibit | FI6934 | FI 6934 | Cholecystokinin receptor | Cholecystokinin | Ceruletide | CCK Receptor |
| Inhibitors Related | PHA-767491 | GV-150013X | CCKBR agonist-2 | (Iso)-FK-480 | Itriglumide | Caerulein, desulfated | GV150013 | Lintitript | N-Cbz-DL-tryptophan | A-65186 | Pranazepide | Spiroglumide |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Peptide Compound Library | NO PAINS Compound Library |
United States
